Ethical issues in psychopharmacology.
The marketing of selective serotonin reuptake inhibitors in the psychopharmacological industry presents a serious moral problem for the corporate model of medicine. In this paper I examine ethical issues relating to the efficacy and safety of these drugs. Pharmaceutical companies have a moral obligation to disclose all information in their possession bearing on the true risks and benefits of their drugs. Only then can patients make fully informed decisions about their treatment.
McHenry
L
L
California State University, Northridge, Department of Philosophy, 18111 Nordhoff Street, Northridge, California 91330-8253, USA. lmchenry@earthlink.net
D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D001294:Attitude to Health; D026688:Bioethical Issues; D003866:Depressive Disorder / Q000188:drug therapy; D004345:Drug Industry / Q000941:ethics*; D006801:Humans; D008389:Marketing of Health Services / Q000941:ethics* / Q000379:methods; D028681:Moral Obligations; D010353:Patient Education as Topic / Q000941:ethics; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D018687:Antidepressive Agents, Second-Generation; D017367:Selective Serotonin Reuptake Inhibitors